Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV

Drug Metabolism and Disposition

Volumn 33, Issue 4, 2005, Pages 587-595

  Walker, Don K ^a   Abel, Samantha ^a   Comby, Pierre ^b   Muirhead, Gary J ^a   Nedderman, Angus N R ^a   Smith, Dennis A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MARAVIROC; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPECIES DIFFERENTIATION; TRANSCYTOSIS;

ADOLESCENT; ADULT; ANIMALS; ANTI-HIV AGENTS; BILE; BLOOD PROTEINS; CACO-2 CELLS; CROSS-OVER STUDIES; CYCLOHEXANES; DOGS; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; INTESTINES; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; P-GLYCOPROTEIN; PERMEABILITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR5; SPECIES SPECIFICITY; TRIAZOLES;

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 15344350690     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002626     Document Type: Article

References (26)

1. Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, et al. (2001) Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 31:665-676.
2. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
3. Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974.
4. Bayes M, Rabasseda X, and Prous JR (2003) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 25:145-168.
5. Beaumont K, Harper A, Smith DA, and Bennett J (2000) The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist UK-224,671. Eur J Pharm Sci 12:41-50.
6. Chantry D (2004) HIV entry and fusion inhibitors. Expert Opin Emerg Drugs 9:1-7.
7. Chassaing C, Luckwell J, Macrae P, Saunders, Wright P, and Venn R (2001) Direct analysis of crude plasma samples by turbulent flow chromatography/tandem mass spectrometry. Chromatographia 53:122-130.
8. Doige CA and Sharom FJ (1992) Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1109: 161-171.
9. Dressman JB, Amidon GL, Reppas C, and Shah VF (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (NY) 15:11-22.
10. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L-B, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002) Application of three-dimensional quantitative structure-activity relationships to P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
11. Gramatté T, Oertel R, Terhaag B, and Kirch W (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker valinolol in humans. Clin Pharmacol Ther 59:541-549.
12. Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, and Morgan P (2004) Nonlinear oral pharmacokinetics of the α-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4- (morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl] qunoline in humans: use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197-204.
13. He Y-L, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, Eastmond R, and Rowland M (1998) Species differences in size discrimination in the paracellular pathway reflected by the oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 87:626-633.
14. Hop CECA, Wang Z, Chen Q, and Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-903.
15. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3-25.
16. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, and Landau NR (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86:367-377.
17. Kwon Y and Inskeep PB (1996) Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs. Pharm Res (NY) 13:566-569.
18. Müller M and Jansen PLM (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285-G1303.
19. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. (1996) Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (Lond) 382:722-725.
20. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, et al. (2000) Bioanalytical method validation-a revisit with a decade of progress. Pharm Res (NY) 17:1551-1557.
21. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, and Langguth P (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
22. Stouch TR and Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Delivery Rev 54:315-328.
23. van de Waterbeemd H, Smith DA, Beaumont K, and Walker DK (2001) Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
24. Walker DK, Dack KN, Dickinson RP, Fenner KS, James K, Rawson DJ, and Smith DA (2001) Absorption, distribution, metabolism and excretion considerations in selection of orally active indole-containing endothelin antagonist. Drug Metab Dispos 29:1424-1431.
25. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944-3948.
26. Zhang Y and Benet LZ (1998) Characterization of P-glycoprotein mediated transport of KO2, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 monolayers. Pharm Res (NY) 15:1520-1524.